Market closed
Arvinas/$ARVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ticker
$ARVN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
430
Website
Arvinas Metrics
BasicAdvanced
$571M
-
-$2.77
1.88
-
Price and volume
Market cap
$571M
Beta
1.88
52-week high
$46.62
52-week low
$7.91
Average daily volume
1.8M
Financial strength
Current ratio
4.644
Quick ratio
4.583
Long term debt to equity
1.406
Total debt to equity
1.727
Management effectiveness
Return on assets (TTM)
-13.05%
Return on equity (TTM)
-32.56%
Valuation
Price to revenue (TTM)
2.266
Price to book
1.02
Price to tangible book (TTM)
1.02
Price to free cash flow (TTM)
-2.286
Growth
Revenue change (TTM)
235.54%
Earnings per share change (TTM)
-58.20%
3-year revenue growth (CAGR)
70.01%
3-year earnings per share growth (CAGR)
-10.20%
What the Analysts think about Arvinas
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arvinas stock.
Arvinas Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Arvinas Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Arvinas News
AllArticlesVideos
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Benzinga·2 days ago
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
GlobeNewsWire·2 days ago
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arvinas stock?
Arvinas (ARVN) has a market cap of $571M as of March 13, 2025.
What is the P/E ratio for Arvinas stock?
The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of March 13, 2025.
Does Arvinas stock pay dividends?
No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Arvinas dividend payment date?
Arvinas (ARVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Arvinas?
Arvinas (ARVN) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.